Showing 1,658 news articles about Hepatitis & HIV

Filters Content type: Editors' picks Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

New & experimental hepatitis C treatment

Gilead's CEO Says New Hepatitis C Drug Attracts Payers

Editor's pick
Bloomberg Businessweek
13 February 2014
Hepatitis C treatment

The global AIDS response can help in fighting hepatitis C

Editor's pick
Washington Post
13 February 2014
Hepatitis C transmission & prevention

Slings, Slamming and Chem-sex

Editor's pick
Huffington Post UK
11 February 2014
New & experimental hepatitis C treatment

Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C

Editor's pick
Gilead press release
11 February 2014
Hepatitis C transmission & prevention

Canada installs first ever crack-pipe vending machines

Editor's pick
The Independent
10 February 2014
Hepatitis C transmission & prevention

Georgia Launches Programme to Curb Hepatitis

Editor's pick
Institiute for War & Peace Reporting
10 February 2014
New & experimental hepatitis C treatment

New hepatitis C pill lifts Gilead's 4Q sales

Editor's pick
Bloomberg Businessweek
7 February 2014
New & experimental hepatitis C treatment

Gilead to license hepatitis C drug to lower-cost manufacturers in India

Editor's pick
Reuters
6 February 2014
New & experimental hepatitis C treatment

Gilead, local generic players in talks to bring hepatitis C drug into India

Editor's pick
The Hindu
4 February 2014
New & experimental hepatitis C treatment

Abbvie Strong Hep C Drug Data and the Looming Battle With Gilead Sciences

Editor's pick
The Street
3 February 2014
Chemsex & recreational drug use

Meth: interview with DJ Fat Tony on sex party drug behind HIV rise in London gay scene

Editor's pick
Channel 4 News
31 January 2014
New & experimental hepatitis C treatment

AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1

Editor's pick
AbbVie press release
31 January 2014
Access to healthcare

At $84000 Gilead Hepatitis C Drug Sets Off Payer Revolt

Editor's pick
Bloomberg
27 January 2014
Hepatitis B

Booster Shots Needed for People with HIV?

Editor's pick
BETA blog
26 January 2014
New & experimental hepatitis C treatment

Only just the beginning of the end of hepatitis C

Editor's pick
The Lancet (editorial)
26 January 2014
Hepatitis C treatment

Victrelis (boceprevir) label changes update contraindications and drug interactions

Editor's pick
FDA
23 January 2014
New & experimental hepatitis C treatment

Hep C drug deleobuvir pulled from clinical study, citing high rate of early discontinuations

Editor's pick
Project Inform
21 January 2014
New & experimental hepatitis C treatment

European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection

Editor's pick
Gilead press release
17 January 2014
New & experimental hepatitis C treatment

Bristol-Myers Ties Hepatitis C Success to Gilead’s Pill

Editor's pick
Bloomberg
14 January 2014
New & experimental hepatitis C treatment

What Is a Hepatitis C Drug Worth?

Editor's pick
Roll Call
14 January 2014
Hepatitis C transmission & prevention

Prevalence of hepatitis C infection found to vary widely among Hispanics

Editor's pick
Medical Xpress
14 January 2014
New & experimental hepatitis C treatment

Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones

Editor's pick
Achillion press release
14 January 2014
New & experimental hepatitis C treatment

Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C

Editor's pick
Vertex press release
9 January 2014
New & experimental hepatitis C treatment

Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency

Editor's pick
Bristol-Myers Squibb press release
8 January 2014